In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.
Natasha Khrystolubova, BPharm, RPh, BCOP
Advertisement
Articles by Natasha Khrystolubova, BPharm, RPh, BCOP
Advertisement
Latest Updated Articles
Expert Commentary on the product profile of Belzutifan for Renal Cell CarcinomaPublished: January 18th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
FDA Approves Revumenib in R/R NPM1-Mutant AML
5
